CA2307850A1 - Use of macrolides for the treatment of cancer and macular degeneration - Google Patents

Use of macrolides for the treatment of cancer and macular degeneration Download PDF

Info

Publication number
CA2307850A1
CA2307850A1 CA002307850A CA2307850A CA2307850A1 CA 2307850 A1 CA2307850 A1 CA 2307850A1 CA 002307850 A CA002307850 A CA 002307850A CA 2307850 A CA2307850 A CA 2307850A CA 2307850 A1 CA2307850 A1 CA 2307850A1
Authority
CA
Canada
Prior art keywords
substituted
heteroaryl
aryl
previously defined
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002307850A
Other languages
English (en)
French (fr)
Inventor
Yat Sun Or
Jacob J. Plattner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2307850A1 publication Critical patent/CA2307850A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA002307850A 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration Abandoned CA2307850A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96147397A 1997-10-31 1997-10-31
US08/961,473 1997-10-31
PCT/US1998/023043 WO1999022722A2 (en) 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration

Publications (1)

Publication Number Publication Date
CA2307850A1 true CA2307850A1 (en) 1999-05-14

Family

ID=25504514

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002307850A Abandoned CA2307850A1 (en) 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration

Country Status (17)

Country Link
EP (1) EP1027060A2 (sk)
JP (1) JP2001521891A (sk)
KR (1) KR20010031577A (sk)
CN (1) CN1278178A (sk)
AR (1) AR043071A1 (sk)
AU (1) AU1206799A (sk)
BG (1) BG104436A (sk)
BR (1) BR9813318A (sk)
CA (1) CA2307850A1 (sk)
HU (1) HUP0100012A3 (sk)
IL (1) IL135518A0 (sk)
NO (1) NO20002189L (sk)
PL (1) PL340604A1 (sk)
SK (1) SK6172000A3 (sk)
TR (1) TR200001147T2 (sk)
WO (1) WO1999022722A2 (sk)
ZA (1) ZA989885B (sk)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079520A1 (en) 2000-04-13 2001-10-25 Biotica Technology Limited Hybrid glycosylated products and their production and use
PT1539157E (pt) 2002-09-18 2013-10-04 Univ Pennsylvania Rapamicina para utilização na inibição ou prevenção de neovascularização coroidal
AR043050A1 (es) 2002-09-26 2005-07-13 Rib X Pharmaceuticals Inc Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
CA2520377A1 (en) 2003-03-28 2004-10-14 Cornell Research Foundation, Inc. Migrastatin analog compositions and uses thereof
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
CN108101948A (zh) * 2004-02-27 2018-06-01 瑞伯-X医药品有限公司 大环化合物以及其制作和使用方法
US8202843B2 (en) * 2004-02-27 2012-06-19 Rib-X Pharmaceuticals, Inc. Macrocyclic compounds and methods of making and using the same
JP5149001B2 (ja) 2004-05-25 2013-02-20 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の処置におけるマイグラスタチンアナログ
EP1805161B1 (en) 2004-09-23 2014-05-07 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
ES2564194T3 (es) 2005-02-09 2016-03-18 Santen Pharmaceutical Co., Ltd. Formulaciones líquidas para el tratamiento de enfermedades o dolencias
PL1904056T3 (pl) 2005-07-18 2009-09-30 Minu Llc Zastosowanie makrolidu do przywracania czucia rogówkowego
WO2007025089A2 (en) 2005-08-24 2007-03-01 Rib-X Pharmaceutical, Inc. Triazole compounds and methods of making and using the same
ES2638427T3 (es) 2005-08-24 2017-10-20 Melinta Therapeutics, Inc. Compuestos de triazol y procedimientos de preparación y uso del mismo
BRPI0707612B8 (pt) 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
CN106317146B (zh) * 2015-06-18 2019-06-21 沈阳药科大学 双环克拉霉素衍生物及其作为肿瘤细胞增值抑制剂的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6461090A (en) * 1989-10-30 1991-05-02 Abbott Laboratories Injectable formulation for lipophilic drugs
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity

Also Published As

Publication number Publication date
IL135518A0 (en) 2001-05-20
SK6172000A3 (en) 2001-03-12
PL340604A1 (en) 2001-02-12
NO20002189D0 (no) 2000-04-27
AR043071A1 (es) 2005-07-20
CN1278178A (zh) 2000-12-27
WO1999022722A2 (en) 1999-05-14
BR9813318A (pt) 2000-08-22
EP1027060A2 (en) 2000-08-16
HUP0100012A3 (en) 2003-07-28
HUP0100012A2 (hu) 2001-05-28
TR200001147T2 (tr) 2000-08-21
NO20002189L (no) 2000-06-28
KR20010031577A (ko) 2001-04-16
ZA989885B (en) 1999-05-05
BG104436A (en) 2000-12-29
AU1206799A (en) 1999-05-24
JP2001521891A (ja) 2001-11-13
WO1999022722A3 (en) 1999-08-05

Similar Documents

Publication Publication Date Title
CA2307850A1 (en) Use of macrolides for the treatment of cancer and macular degeneration
US5827895A (en) Hexahydrolupulones useful as anticancer agents
JPH0349893B2 (sk)
JPH06263635A (ja) 抗腫瘍性を有する避妊および月経周期調節用薬剤、その使用方法とその製法
EP1025114B1 (en) 3'-n-modified 6-o-substituted erythromycin ketolide derivatives having antibacterial activity
HU211337A9 (en) 4"-deoxyerythromycin derivatives
CN1269803A (zh) 6,9－桥红霉素衍生物
SK13162001A3 (sk) 6-o-substituované makrolidy majúce antibakteriálnu aktivitu
EP1167375A1 (en) Erythromycin derivatives
US6034069A (en) 3-'N-modified 6-O-substituted erythromycin ketolide derivatives having antibacterial activity
CA2218916A1 (en) Dialkyltiacumicin compounds
JP2003507487A (ja) 抗菌活性を有する９ａ−アザライド類
JP2004529921A (ja) ロイコマイシンから誘導された９−アミノ−１４員環マクロライド
CN113116859B (zh) 阿奇霉素丸芯包衣制剂
CZ20001524A3 (cs) Farmaceutický přípravek pro léčení nádorů a makulární degenerace
US6716820B1 (en) 6-O-substituted bicyclic macrolides
CA2398848C (en) Anti-infective agents useful against multidrug-resistant strains of bacteria
WO2002094183A2 (en) A method for tumor treatment with fumagillol derivatives
WO2023134707A1 (en) Methods for treating aml-mrc and mds
US5217960A (en) Erythromycin derivatives
WO2023195570A1 (ko) 슈퍼옥시드 디스무타아제를 포함하는 항암 조성물
US20040209827A1 (en) 11-C-substituted derivatives of clarithromycin
EP1258248A2 (en) Tumor treatments comprising a fumagillol derivative and a further antineoplastic agent
CN107569493A (zh) 氟维司群在制备治疗无功能垂体腺瘤的药物中的用途
WO1998011883A1 (en) Use of hexahydrolupulones as antibacterial agents

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued